Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.3730
+0.0032 (0.87%)
At close: Sep 4, 2026, 4:00 PM EDT
0.3651
-0.0079 (-2.12%)
After-hours: Sep 4, 2026, 7:30 PM EDT
Scienture Holdings Revenue
Scienture Holdings had revenue of $343.64K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $821.32K, up 540.64% year-over-year. In the year 2025, Scienture Holdings had annual revenue of $431.61K with 215.87% growth.
Revenue (ttm)
$821.32K
Revenue Growth
+540.64%
P/S Ratio
18.65
Revenue / Employee
$91,257
Employees
9
Market Cap
15.32M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 431.61K | 294.97K | 215.87% |
| Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
| Dec 31, 2023 | 1.36M | -8.89M | -86.69% |
| Dec 31, 2022 | 10.25M | 360.74K | 3.65% |
| Dec 31, 2021 | 9.89M | -7.23M | -42.24% |
| Dec 31, 2020 | 17.12M | 9.69M | 130.26% |
| Dec 31, 2019 | 7.44M | 3.60M | 94.07% |
| Dec 31, 2018 | 3.83M | 900.50K | 30.72% |
| Dec 31, 2017 | 2.93M | 449.41K | 18.11% |
| Dec 31, 2016 | 2.48M | -430.66K | -14.79% |
| Dec 31, 2015 | 2.91M | 1.42M | 94.66% |
| Dec 31, 2014 | 1.50M | 540.35K | 56.53% |
| Dec 31, 2013 | 955.88K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 97.93B |
| Eli Lilly and Company | 79.67B |
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| NeuroOne Medical Technologies | 12.47M |
| Vyome Holdings | 129.73K |
| Lisata Therapeutics | 100.00K |
SCNX News
- 11 days ago - DataMeds AI and Tollo Health Announce Fall 2026 Cold & Flu #Back2School50% Marketing Campaign for Viral Infections Medical Food Galectovid(TM) - Accesswire
- 21 days ago - DataMeds AI Reports Second Quarter 2026 Financials and Provides Business Update - Accesswire
- 21 days ago - Scienture announces commercial launch of Rezenopy Nasal Spray - TheFly
- 23 days ago - DataMEDS AI Announces Its Board of Directors Approved September 9, 2026 as the Payment Date of the Previously Announced Distribution of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of August 7, 2026 - Accesswire
- 24 days ago - SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance - GlobeNewsWire
- 26 days ago - SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - GlobeNewsWire
- 26 days ago - DataMeds AI Provides Update on Corexa Health's Pharmacy Division - Accesswire
- 4 weeks ago - DataMeds AI Renames Pharmacy Subsidiaries Corexa Pharmacy and Corexa Tech & Hub Under New Corexa Health Division - Accesswire